- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01423916
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
29 settembre 2015 aggiornato da: Otsuka Pharmaceutical Development & Commercialization, Inc.
A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects. The goals of this trial are three-fold:
- To determine the effect of OPC-34712 on the individual QT interval (QTcI) corrected for placebo
- To determine the effect of moxifloxacin on QTcI
- To examine the concentration-effect relationship of OPC-34712 and moxifloxacin on QTcI
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
218
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
California
-
Long Beach, California, Stati Uniti, 90806
- Otsuka Investigational Site
-
San Diego, California, Stati Uniti, 92102
- Otsuka Investigational Site
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Otsuka Investigational Site
-
-
Kansas
-
Overland Park, Kansas, Stati Uniti, 66212
- Otsuka Investigational Site
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20850
- Otsuka Investigational Site
-
-
Missouri
-
St. Louis, Missouri, Stati Uniti, 63118
- Otsuka Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19139
- Otsuka Investigational Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78754
- Otsuka Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 55 anni (Adulto)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Male and female subjects between 18 and 55 years of age, inclusive, with a diagnosis of schizophrenia or schizoaffective disorder as defined by DSM-IV-TR criteria.
- Body mass index of 19 to 35 kg/m2.
Exclusion Criteria:
- Females who are pregnant or lactating. A negative serum pregnancy test must be confirmed prior to the first dose of trial medication for all female subjects.
- Subjects presenting with a first episode of schizophrenia or schizoaffective disorder based on the clinical judgment of the investigator.
- Subjects who have received continuous medication therapy to treat schizophrenia or schizoaffective disorder for less than 6 months prior to washout.
- Subjects with schizophrenia or schizoaffective disorder that are considered resistant/refractory to antipsychotic treatment by history, who have a history of failure to clozapine, or who are responsive only to clozapine treatment.
- Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia or schizoaffective disorder.
- Hospitalization for an exacerbation of schizophrenia or schizoaffective disorder within 3 months prior to randomization.
- Subjects who have a history of or who have evidence of other medical and/or neurological conditions that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the trial.
- Subjects with a history of neuroleptic malignant syndrome.
- Subjects with a history of seizure disorder.
- Subjects who meet DSM-IV-TR criteria for substance dependence within 6 months prior to randomization.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Arm 1 (OPC-34712, placebo)
Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
|
Arms assigned to this intervention receive 4mg.
OPC-34712 placebo
|
Comparatore attivo: Arm 2 (OPC-34712, placebo)
Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
|
OPC-34712 placebo
Arms assigned to this intervention receive 12mg.
|
Comparatore attivo: Arm 3 (moxifloxacin, placebo)
Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
|
OPC-34712 placebo
Arms assigned to this intervention will receive 400mg.
|
Comparatore attivo: Arm 4 (moxifloxacin, placebo)
Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
|
OPC-34712 placebo
Arms assigned to this intervention will receive 400mg.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.
Lasso di tempo: Day 11 (Hours 1, 2, 3, 4, 5, 6, 8, 12, 16, 24)
|
Pharmacodynamics endpoint is the time-matched corrected QT interval (QTcI) change from baseline (Day -1) corrected for placebo on Day 11 following brexpiprazole treatment.
The primary QT to QTc correction formula (QTcI) was determined for each participant using the participant's baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k was derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
|
Day 11 (Hours 1, 2, 3, 4, 5, 6, 8, 12, 16, 24)
|
Number of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).
Lasso di tempo: AEs were recorded from Screening (informed consent was signed) during the 12-day treatment period to follow-up 30 (+ 2) days post-last dose of study medication
|
Clinically important changes in vital signs, physical examinations, laboratory tests and ECGs were by and large reflected in AE/SAE (which are presented in safety section) of this report.
|
AEs were recorded from Screening (informed consent was signed) during the 12-day treatment period to follow-up 30 (+ 2) days post-last dose of study medication
|
Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.
Lasso di tempo: Day 11
|
Pharmacokinetics endpoint is the maximum (peak) plasma concentration (Cmax) of brexpiprazole and moxifloxacin.
Values for Cmax were determined directly from the observed data.
Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
|
Day 11
|
Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.
Lasso di tempo: Day 11
|
Pharmacokinetics endpoint is the time to maximum (peak) plasma concentration (tmax) of brexpiprazole and moxifloxacin.
Values for tmax were determined directly from the observed data.
Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
|
Day 11
|
Area Under the Plasma Concentration-time Curve During Dosing (AUCT).
Lasso di tempo: Day 11
|
Pharmacokinetics endpoint is the area under the concentration-time curve from time zero to 24 hours (AUC0-24h) of brexpiprazole and moxifloxacin.
Area under the plasma concentration-time curve during the dosing interval at steady-state (AUCT) value was estimated using the linear trapezoidal rule; the value reported represent the area under the curves to the last time point during that day.
Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
|
Day 11
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.
Lasso di tempo: Baseline, Day 11
|
New onset (> 450, > 480, or > 500 msec) in QTc was defined as a participant who attained a QTc > 450, > 480, > 500 msec during Day 11 but not on Day -1.
The number of participants were noted with time-matched change in mean QTcI change from Baseline for assay sensitivity of moxifloxacin treatment corrected for placebo.
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
|
Baseline, Day 11
|
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).
Lasso di tempo: Baseline, Day 11
|
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
The change form Baseline in summary of maximun QTcI on Day 11 minus mean QTcI on Day -1 (Baseline) is presented here.
|
Baseline, Day 11
|
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).
Lasso di tempo: Baseline, Day 11
|
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
The change from Baseline in summary of maximum QTcI on Day 11 minus maximum QTcI on Day -1 (Baseline) is presented here.
|
Baseline, Day 11
|
Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.
Lasso di tempo: Day 11
|
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
Participants with QTcI interval change between 30 to 60 msec were presented here.
|
Day 11
|
Number of Participants With QTcI Interval > 60 Msec on Day 11.
Lasso di tempo: Day 11
|
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data.
The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
Participants with QTcI interval change of > 60 msec on Day 11 were presented here.
|
Day 11
|
Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.
Lasso di tempo: Day 11
|
The number of participants who were noted with new incidence of QT interval of > 500 msec on Day 11 and a 12-lead ECG was used.
|
Day 11
|
Number of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.
Lasso di tempo: Day 11
|
Participants with incidence of ECG morphology abnormalities on Day 11 (participants who had abnormalities during Day 11 but not at Day -1) were noted.
Types of abnormalities included appearance of abnormal U waves, negative T waves, elevation of ST segment, depression of ST segment, second degree heart block, third degree heart block, right bundle branch block, and left bundle branch block.
ECGs were sampled at predose and approximately 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose on Days -1, 1, 11, and 12.
|
Day 11
|
Number of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.
Lasso di tempo: Day 11
|
Changes in HR with values 25% decrease from Day -1 and HR < 50 bpm and 25% increase from Day -1 and HR > 100 bpm; PR interval of greater than or equal to 25% change from Day -1 and PR > 200 msec; QRS interval of Greater than or equal to 25% change from Day -1 and > 100 msec were noted on Day 11.
Maximum change from baseline to the on-treatment ECG values on Day 11 for heart rate.
|
Day 11
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 luglio 2011
Completamento primario (Effettivo)
1 febbraio 2012
Completamento dello studio (Effettivo)
1 marzo 2012
Date di iscrizione allo studio
Primo inviato
8 agosto 2011
Primo inviato che soddisfa i criteri di controllo qualità
25 agosto 2011
Primo Inserito (Stima)
26 agosto 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
29 ottobre 2015
Ultimo aggiornamento inviato che soddisfa i criteri QC
29 settembre 2015
Ultimo verificato
1 settembre 2015
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Spettro della schizofrenia e altri disturbi psicotici
- Schizofrenia
- Disturbi psicotici
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della topoisomerasi II
- Inibitori della topoisomerasi
- Agenti antibatterici
- Moxifloxacina
Altri numeri di identificazione dello studio
- 331-10-242
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su OPC-34712 (4mg)
-
Otsuka Pharmaceutical Co., Ltd.Completato
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoSchizofreniaStati Uniti, Bulgaria, Filippine, Romania, Federazione Russa, Serbia, Croazia, India, Corea, Repubblica di, Slovacchia, Taiwan, Ucraina
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoSchizofreniaCorea, Repubblica di, Stati Uniti, Filippine, Malaysia, Croazia, Serbia, Federazione Russa, Ucraina, Romania, Porto Rico, Colombia, Tacchino, Polonia, Taiwan, Canada, Lettonia, Slovacchia, Messico, Giappone
-
Otsuka Pharmaceutical Development & Commercialization...Completato
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.Completato
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoSchizofrenia acutaStati Uniti, Filippine, Taiwan, Federazione Russa, Croazia, Colombia, Messico, Slovacchia
-
Otsuka Pharmaceutical Co., Ltd.CompletatoSchizofreniaGiappone
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoDisordini mentali | Disordine depressivo | Depressione | Disturbi dell'umore | Disturbo depressivo, maggioreStati Uniti, Francia, Polonia, Canada, Slovacchia
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoDisordini mentali | Disordine depressivo | Depressione | Disturbi dell'umore | Disturbo depressivo, maggioreStati Uniti, Federazione Russa, Ungheria, Romania, Ucraina, Canada, Germania
-
Otsuka Pharmaceutical Development & Commercialization...CompletatoDisturbo depressivo maggioreStati Uniti